Split (1)

train · 3.45k rows

pbs_code stringclasses 390 values	drug stringclasses 18 values	brand stringclasses 32 values	formulation stringclasses 38 values	indication stringclasses 8 values	treatment_phase stringclasses 57 values	streamlined_code float64 9.19k 16.9k ⌀	online_application bool 2 classes	authority_method stringclasses 2 values	hospital_type stringclasses 3 values	maximum_prescribable_pack float64 1 5	maximum_quantity_units float64 1 180	number_of_repeats float64 0 6	schedule_code stringdate 2025-07-01 00:00:00 2025-08-01 00:00:00	schedule_year int64 2.03k 2.03k	schedule_month stringclasses 2 values
9090K	Etanercept	Brenzys	Injections 50 mg in 1 mL single use pre-filled syringes, 4	rheumatoid arthritis	First continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	1	5	2025-08	2,025	AUGUST
9090K	Etanercept	Enbrel	Injections 50 mg in 1 mL single use pre-filled syringes, 4	rheumatoid arthritis	First continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	1	5	2025-08	2,025	AUGUST
9099X	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9099X	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9099X	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9099X	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9099X	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9099X	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9099X	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9099X	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9099X	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9099X	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9099X	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9099X	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9099X	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9099X	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9099X	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9099X	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9100Y	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9100Y	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9100Y	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9100Y	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9100Y	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	First continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9100Y	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	First continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9100Y	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	First continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9100Y	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	First continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9101B	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9101B	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9101B	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9101B	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9101B	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9101B	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9101B	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9101B	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9101B	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9101B	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9101B	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9101B	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9101B	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9101B	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9101B	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9101B	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9102C	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9102C	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9102C	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9102C	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9102C	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9102C	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9102C	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9102C	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9102C	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9102C	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9102C	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9102C	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9103D	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9103D	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9103D	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9103D	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9103D	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9103D	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9103D	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9103D	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9103D	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9103D	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9103D	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9103D	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9103D	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9103D	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9103D	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9103D	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	3	2025-08	2,025	AUGUST
9104E	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9104E	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9104E	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9104E	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9104E	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9104E	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9104E	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9104E	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9104E	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9104E	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9104E	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9104E	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	2	5	2025-08	2,025	AUGUST
9455P	Etanercept	Brenzys	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	1	1	3	2025-08	2,025	AUGUST
9455P	Etanercept	Enbrel	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	1	1	3	2025-08	2,025	AUGUST
9455P	Etanercept	Nepexto	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	1	1	3	2025-08	2,025	AUGUST
9455P	Etanercept	Brenzys	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	1	3	2025-08	2,025	AUGUST
9455P	Etanercept	Enbrel	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	1	3	2025-08	2,025	AUGUST
9455P	Etanercept	Nepexto	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	1	3	2025-08	2,025	AUGUST
9455P	Etanercept	Brenzys	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	1	3	2025-08	2,025	AUGUST
9455P	Etanercept	Enbrel	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	1	3	2025-08	2,025	AUGUST
9455P	Etanercept	Nepexto	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	1	1	3	2025-08	2,025	AUGUST
9455P	Etanercept	Brenzys	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	1	3	2025-08	2,025	AUGUST
9455P	Etanercept	Enbrel	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	1	3	2025-08	2,025	AUGUST
9455P	Etanercept	Nepexto	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	1	3	2025-08	2,025	AUGUST
9456Q	Etanercept	Brenzys	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	1	5	2025-08	2,025	AUGUST
9456Q	Etanercept	Enbrel	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	1	5	2025-08	2,025	AUGUST
9456Q	Etanercept	Nepexto	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	1	1	5	2025-08	2,025	AUGUST
9456Q	Etanercept	Brenzys	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	1	5	2025-08	2,025	AUGUST
9456Q	Etanercept	Enbrel	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	1	5	2025-08	2,025	AUGUST
9456Q	Etanercept	Nepexto	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	1	1	5	2025-08	2,025	AUGUST

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.